Clinical Trials Logo

Clinical Trial Summary

More than 50% of ICU patients suffer from Acute kidney injury (AKI). Metformin shows protective properties in kidney disease. Our study aimed to validate AKI incidence among diabetes patients in the ICU with or without preadmission metformin exposure. We included non-AKI patients with type 2 diabetes in Medical Information Mart for Intensive Care (MIMIC)-III database. Incidence of AKI and mortality were compared between those with and without preadmission prescriptions.


Clinical Trial Description

Emerged as a major public healthy problem, Acute kidney injury (AKI) is now influencing millions of people worldwide and leading to reduced survival, increased progression of latent chronic kidney disease (CKD), and even new onset of CKD. More than half of intensive care unit (ICU) patients underwent AKI in a recent multinational cross-sectional study, often resulting in the need for renal replacement therapy with a high socio-economic impact for the patients.The effective precaution and treatment strategy remains limited. As the most general and first-line biguanide antihyperglycemic drug, metformin has anti-inflammatory characteristics and is related with decreased all-cause mortality compared with other antihyperglycemics.. In some clinical trials and experimental studies conducted on divergent rodent models representing various types of kidney diseases going from AKI to CKD, metformin has been shown beneficial effects on the kidney. Moreover, preadmission metformin exposure is associated with a lower rate of 28-day mortality among AKI patients showed in several clinical studies. However, in critical care patients with type 2 diabetes, the evidence of preadmission metformin usage decreasing a risk of AKI incidence is still absented. Therefore we performed a retrospective cohort study to validate the association of preadmission metformin exposure and AKI incidence in patients with diabetes in the ICU . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04631289
Study type Observational
Source Second Affiliated Hospital of Guangzhou Medical University
Contact
Status Completed
Phase
Start date August 1, 2020
Completion date November 10, 2020

See also
  Status Clinical Trial Phase
Completed NCT04112953 - Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Recruiting NCT04597034 - Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19 N/A
Completed NCT04458571 - Effect of CRRT Duration on Solute Removal
Recruiting NCT04114747 - Renal Physiology During Continuous Renal Replacement Therapy N/A
Completed NCT05094154 - Effect of Antibiotic Choice On ReNal Outcomes (ACORN) Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Recruiting NCT04351906 - Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome N/A
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Completed NCT04762524 - The Impact of CRRT Modality on Filter Life N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Completed NCT04788394 - Renal Involvement in Hospitalized Children With COVID-19
Recruiting NCT04474249 - Follow-up of Critical COVID-19 Patients
Completed NCT04517630 - Renal Biomarkers in AKI and COVID-19
Completed NCT04407156 - Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
Recruiting NCT04895384 - El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
Completed NCT03070353 - Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury Phase 2/Phase 3